Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,628
archived clinical trials in
Schizophrenia

A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated:  7/5/2013
CRI Worldwide, LLC
430
mi
from 43215
Willingboro, NJ
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated: 7/5/2013
CRI Worldwide, LLC
430
mi
from 43215
Willingboro, NJ
Click here to add this to my saved trials
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated:  7/5/2013
Erie County Medical Center, Corp
294
mi
from 43215
Buffalo, NY
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated: 7/5/2013
Erie County Medical Center, Corp
294
mi
from 43215
Buffalo, NY
Click here to add this to my saved trials
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated:  7/5/2013
Neurobehavioral Research, Inc.
491
mi
from 43215
Cedarhurst, NY
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated: 7/5/2013
Neurobehavioral Research, Inc.
491
mi
from 43215
Cedarhurst, NY
Click here to add this to my saved trials
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated:  7/5/2013
Comprehensive Clinical Development, Inc
489
mi
from 43215
Fresh Meadows, NY
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated: 7/5/2013
Comprehensive Clinical Development, Inc
489
mi
from 43215
Fresh Meadows, NY
Click here to add this to my saved trials
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated:  7/5/2013
Finger Lakes Clinical Research
356
mi
from 43215
Rochester, NY
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated: 7/5/2013
Finger Lakes Clinical Research
356
mi
from 43215
Rochester, NY
Click here to add this to my saved trials
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated:  7/5/2013
Behavioral Medical Research of Staten Island
473
mi
from 43215
Staten Island, NY
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated: 7/5/2013
Behavioral Medical Research of Staten Island
473
mi
from 43215
Staten Island, NY
Click here to add this to my saved trials
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated:  7/5/2013
Oklahoma Clinical Research
849
mi
from 43215
Oklahoma City, OK
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated: 7/5/2013
Oklahoma Clinical Research
849
mi
from 43215
Oklahoma City, OK
Click here to add this to my saved trials
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated:  7/5/2013
Cutting Edge Research Group
849
mi
from 43215
Oklahoma City, OK
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated: 7/5/2013
Cutting Edge Research Group
849
mi
from 43215
Oklahoma City, OK
Click here to add this to my saved trials
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated:  7/5/2013
CRI Worldwide - Kirkbride
416
mi
from 43215
Philadelphia, PA
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated: 7/5/2013
CRI Worldwide - Kirkbride
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated:  7/5/2013
Lincoln Research
618
mi
from 43215
Lincoln, RI
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated: 7/5/2013
Lincoln Research
618
mi
from 43215
Lincoln, RI
Click here to add this to my saved trials
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated:  7/5/2013
FutureSearch Clinical Trials LP
1063
mi
from 43215
Austin, TX
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated: 7/5/2013
FutureSearch Clinical Trials LP
1063
mi
from 43215
Austin, TX
Click here to add this to my saved trials
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated:  7/5/2013
Community Clinical Research
1057
mi
from 43215
Austin, TX
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated: 7/5/2013
Community Clinical Research
1057
mi
from 43215
Austin, TX
Click here to add this to my saved trials
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated:  7/5/2013
Pillar Clinical Research, LLC
903
mi
from 43215
Dallas, TX
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated: 7/5/2013
Pillar Clinical Research, LLC
903
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated:  7/5/2013
FutureSearch Clinical Trials, LP
905
mi
from 43215
Dallas, TX
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated: 7/5/2013
FutureSearch Clinical Trials, LP
905
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated:  7/5/2013
Family Psychiatry of the Woodlands
974
mi
from 43215
The Woodlands, TX
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated: 7/5/2013
Family Psychiatry of the Woodlands
974
mi
from 43215
The Woodlands, TX
Click here to add this to my saved trials
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated:  7/5/2013
Department of Psychiatry, University of Utah Health Sciences Center
1513
mi
from 43215
Salt Lake City, UT
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated: 7/5/2013
Department of Psychiatry, University of Utah Health Sciences Center
1513
mi
from 43215
Salt Lake City, UT
Click here to add this to my saved trials
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated:  7/5/2013
Frontier Institute
1779
mi
from 43215
Spokane, WA
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
Status: Enrolling
Updated: 7/5/2013
Frontier Institute
1779
mi
from 43215
Spokane, WA
Click here to add this to my saved trials
The Influence of Aerobic Exercise on Cognitive Functioning in Schizophrenia.
The Influence of Aerobic Exercise on Cognitive Functioning in Schizophrenia.
Status: Enrolling
Updated:  7/8/2013
Columbia University & New York State Psyciatric Institute
481
mi
from 43215
New York, NY
The Influence of Aerobic Exercise on Cognitive Functioning in Schizophrenia.
The Influence of Aerobic Exercise on Cognitive Functioning in Schizophrenia.
Status: Enrolling
Updated: 7/8/2013
Columbia University & New York State Psyciatric Institute
481
mi
from 43215
New York, NY
Click here to add this to my saved trials
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated:  7/15/2013
Novartis Investigative Site
1967
mi
from 43215
Garden Grove, CA
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated: 7/15/2013
Novartis Investigative Site
1967
mi
from 43215
Garden Grove, CA
Click here to add this to my saved trials
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated:  7/15/2013
Novartis Investigative Site
1967
mi
from 43215
Glendale, CA
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated: 7/15/2013
Novartis Investigative Site
1967
mi
from 43215
Glendale, CA
Click here to add this to my saved trials
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated:  7/15/2013
Novartis Investigative Site
1949
mi
from 43215
National City, CA
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated: 7/15/2013
Novartis Investigative Site
1949
mi
from 43215
National City, CA
Click here to add this to my saved trials
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated:  7/15/2013
Novartis Investigative Site
2098
mi
from 43215
Oakland, CA
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated: 7/15/2013
Novartis Investigative Site
2098
mi
from 43215
Oakland, CA
Click here to add this to my saved trials
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated:  7/15/2013
Novartis Investigative Site
1966
mi
from 43215
Pico Rivera, CA
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated: 7/15/2013
Novartis Investigative Site
1966
mi
from 43215
Pico Rivera, CA
Click here to add this to my saved trials
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated:  7/15/2013
Novartis Investigative Site
1947
mi
from 43215
San Diego, CA
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated: 7/15/2013
Novartis Investigative Site
1947
mi
from 43215
San Diego, CA
Click here to add this to my saved trials
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated:  7/15/2013
Novartis Investigative Site
978
mi
from 43215
Miramar, FL
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated: 7/15/2013
Novartis Investigative Site
978
mi
from 43215
Miramar, FL
Click here to add this to my saved trials
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated:  7/15/2013
Novartis Investigative Site
432
mi
from 43215
Atlanta, GA
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated: 7/15/2013
Novartis Investigative Site
432
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated:  7/15/2013
Novartis Investigative Site
429
mi
from 43215
Marlton, NJ
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated: 7/15/2013
Novartis Investigative Site
429
mi
from 43215
Marlton, NJ
Click here to add this to my saved trials
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated:  7/15/2013
Novartis Investigative Site
467
mi
from 43215
Staten Island, NY
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated: 7/15/2013
Novartis Investigative Site
467
mi
from 43215
Staten Island, NY
Click here to add this to my saved trials
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated:  7/15/2013
Novartis Investigative Site
467
mi
from 43215
Staten Island, NY
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated: 7/15/2013
Novartis Investigative Site
467
mi
from 43215
Staten Island, NY
Click here to add this to my saved trials
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated:  7/15/2013
Novartis Investigative Site
416
mi
from 43215
Philadelphia, PA
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated: 7/15/2013
Novartis Investigative Site
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated:  7/15/2013
Novartis Investigative Site
917
mi
from 43215
Irving, TX
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Status: Enrolling
Updated: 7/15/2013
Novartis Investigative Site
917
mi
from 43215
Irving, TX
Click here to add this to my saved trials
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  7/19/2013
Clinical Research Facility
1943
mi
from 43215
Chino, CA
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 7/19/2013
Clinical Research Facility
1943
mi
from 43215
Chino, CA
Click here to add this to my saved trials
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  7/19/2013
Clinical Research Facility
1967
mi
from 43215
Garden Grove, CA
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 7/19/2013
Clinical Research Facility
1967
mi
from 43215
Garden Grove, CA
Click here to add this to my saved trials
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  7/19/2013
Clinical Research Facility
1949
mi
from 43215
National City, CA
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 7/19/2013
Clinical Research Facility
1949
mi
from 43215
National City, CA
Click here to add this to my saved trials
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  7/19/2013
Clinical Research Facility
1944
mi
from 43215
Oceanside, CA
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 7/19/2013
Clinical Research Facility
1944
mi
from 43215
Oceanside, CA
Click here to add this to my saved trials
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  7/19/2013
Clinical Research Facility
1960
mi
from 43215
Santa Ana, CA
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 7/19/2013
Clinical Research Facility
1960
mi
from 43215
Santa Ana, CA
Click here to add this to my saved trials
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  7/19/2013
Clinical Research Facility
1949
mi
from 43215
San Diego, CA
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 7/19/2013
Clinical Research Facility
1949
mi
from 43215
San Diego, CA
Click here to add this to my saved trials
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  7/19/2013
Clinical Research Facility
1980
mi
from 43215
Torrance, CA
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 7/19/2013
Clinical Research Facility
1980
mi
from 43215
Torrance, CA
Click here to add this to my saved trials
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  7/19/2013
Clinical Research Facility
861
mi
from 43215
Bradenton, FL
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 7/19/2013
Clinical Research Facility
861
mi
from 43215
Bradenton, FL
Click here to add this to my saved trials
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  7/19/2013
Clinical Research Facility
789
mi
from 43215
Maitland, FL
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 7/19/2013
Clinical Research Facility
789
mi
from 43215
Maitland, FL
Click here to add this to my saved trials
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  7/19/2013
Clinical Research Facility
274
mi
from 43215
Chicago, IL
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 7/19/2013
Clinical Research Facility
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  7/19/2013
Clinical Research Facility
302
mi
from 43215
Hoffman Estates, IL
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 7/19/2013
Clinical Research Facility
302
mi
from 43215
Hoffman Estates, IL
Click here to add this to my saved trials
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  7/19/2013
Clinical Research Facility
884
mi
from 43215
Lake Charles, LA
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 7/19/2013
Clinical Research Facility
884
mi
from 43215
Lake Charles, LA
Click here to add this to my saved trials
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  7/19/2013
Clinical Research Facility
394
mi
from 43215
St. Louis, MO
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 7/19/2013
Clinical Research Facility
394
mi
from 43215
St. Louis, MO
Click here to add this to my saved trials
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  7/19/2013
Clinical Research Facility
mi
from 43215
Marlton, NJ
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 7/19/2013
Clinical Research Facility
mi
from 43215
Marlton, NJ
Click here to add this to my saved trials
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  7/19/2013
Clinical Research Facility
491
mi
from 43215
Cedarhurst, NY
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 7/19/2013
Clinical Research Facility
491
mi
from 43215
Cedarhurst, NY
Click here to add this to my saved trials
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  7/19/2013
Clinical Research Facility
477
mi
from 43215
New York, NY
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 7/19/2013
Clinical Research Facility
477
mi
from 43215
New York, NY
Click here to add this to my saved trials
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  7/19/2013
Clinical Research Facility
921
mi
from 43215
DeSoto, TX
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 7/19/2013
Clinical Research Facility
921
mi
from 43215
DeSoto, TX
Click here to add this to my saved trials
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  7/19/2013
Clinical Research Facility
991
mi
from 43215
Houston, TX
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 7/19/2013
Clinical Research Facility
991
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia
A Long-Term Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aripiprazole (OPC 14597) as Maintenance Treatment in Adolescent Patients With Schizophrenia
Status: Enrolling
Updated:  7/22/2013
Clinical Research Facility
1947
mi
from 43215
San Diego, CA
Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia
A Long-Term Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aripiprazole (OPC 14597) as Maintenance Treatment in Adolescent Patients With Schizophrenia
Status: Enrolling
Updated: 7/22/2013
Clinical Research Facility
1947
mi
from 43215
San Diego, CA
Click here to add this to my saved trials